EZH2 cooperates with other oncogenes to accelerate myelodysplastic syndrome, and long-term suppression of EZH2 in glioblastoma causes a significant alteration in cell fate, ultimately leading to tumor progression50. This evidence concerns the gene EZH2 and myelodysplastic syndrome.